You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
【瑞通認股證牛熊證】新經濟股回勇 美團及阿里健康齊挑戰百天線、資金追好倉 恆指牛51258 熊56924/ 美團牛51334 熊59322/ 里康牛61666 熊51856
阿思達克 04-26 10:50
市場消化拜登政府擬上調資本增值稅的消息,配合美國PMI及新屋銷售數據理想,帶動道指上周五收報34043點,升227點(或0.7%)。恆指上周五以全日高位29078點收市,升323點(或1.1%)。今早曾升160點,升抵29200點,惟其後好淡爭持,未能企穩50天線(29169點)。恆指好倉(牛證及認購權證)上周五淨流出逾1億港元(下同),恆指淡倉(熊證及認沽權證)同日淨流入逾1.1億元,反映投資者預期大市連日反彈後將回軟。上周五恆指牛證街貨重貨區為收回價27400至27499點,而熊證街貨重貨區為收回價29800至29899點。

美團(03690)上周五發力抽升,一度飆6.6%至311元以上,收升4.9%報306.4元,是集團公佈大規模集資計劃後首次重上20天線和300元關。美團上周獲科技「女股神」Cathie Wood旗下ARK系列基金增持,美團今早再升逾4%,一度高見321.6元,暫連升三日,短線阻力觀察100天線(約327元)。上周五有逾13億元北水淨買入美團。輪證資金流方面,超過2400萬元淨流出其好倉,淡倉同日則有逾2100萬元淨流入。

有券商報告預料網易(09999)上季收入可按年升19%,非公認會計準則下經營淨利潤則按年跌13%,但同時預期公司在5月舉行的新遊戲發布會可成為股價催化劑。網易上周五收漲4%於174.2元,收復50天線,今早稍為回軟,回至172元附近。上周五有逾50萬元淨流出其好倉,淡倉同日則有小量資金淨流入。

阿里健康(00241)上周五最多飆6.8%,至24.15元逾一個月高,收市維持5.3%升幅,於23.8元,為升幅最大藍籌、國指及科指成份股。股份今早曾升逾1%,重返24元以上。據報集團近日聯合藥企成立天貓好藥聯盟,未來一年內將建設12個藥品倉庫,推進全國物流提速。上周五分別有逾60萬元和逾10萬元淨流入其好倉和淡倉。

藥明生物(02269)重拾強勢,上周五最多升5%,高見115.8元,創兩個月以來高位,收市企115元,20天線升穿50天線出現黃金交叉。全周計累升9.5%,為表現最佳藍籌,並已收復各移動平均線。藥明生物今早再升逾1%,重返116元水平,暫錄三連升。上周五有近4億元北水淨買入藥明。輪證資金流方面,逾540萬元淨流出其好倉,淡倉同日則有近10萬元淨流入。

瑞通相關認股證之選擇:

美團輕微價外、中短期購16108,行使價:345元,2021年9月到期,實際槓桿:5.3倍

美團輕微價外、中短期沽16119,行使價:269.8元,2021年8月到期,實際槓桿:5.4倍

網易價外、中短期購11976,行使價:208.88元,2021年8月到期,實際槓桿:7.8倍

里康價外、中短期購11003,行使價:28.88元,2021年9月到期,實際槓桿:4.4倍

里康貼價、短期沽20457,行使價:23元,2021年7月到期,實際槓桿:5倍

藥明價外、中年期購18757,行使價:150.08元,2021年12月到期,實際槓桿:3.4倍

思摩貼價、中年期購16109,行使價:60.969元,2021年11月到期,實際槓桿:2.1倍

嗶哩輕微價外、中年期購17336,行使價:962.6元,2021年10月到期,實際槓桿:3.6倍

快手輕微價外、中短期 ,行使價:300元,2021年8月到期,實際槓桿:5.2倍

快手輕微價外、中短期沽22413,行使價:233.88元,2021年10月到期,實際槓桿:3.2倍

瑞通相關牛熊證之選擇:

恆指牛證51258,收回價:28760點,槓桿比率:36倍

恆指熊證56924,收回價:29740點,槓桿比率:42倍

美團牛證51334,收回價:280.2元,槓桿比率:7.1倍

美團熊證59322,收回價:346.88元,槓桿比率:9.4倍

網易牛證60132,收回價:152元,槓桿比率:6.7倍

網易熊證53623,收回價:214元,槓桿比率:3.6倍

里康牛證61666,收回價:21.68元,槓桿比率:6.4倍

里康熊證51856,收回價:25.58元,槓桿比率:9.1倍

藥明牛證66183,收回價:101.88元,槓桿比率:5.9倍

藥明熊證61272,收回價:130.8元,槓桿比率:6.7倍

全場最貼思摩牛證50724,收回價:53.08元,槓桿比率:5.5倍

重要風險通知

本結構性產品並無抵押品。

結構性產品之價格一般可急升亦可急跌,有可能損失結構性產品之全部或重大部分購買價,閣下對此應有所準備。

閣下投資前應了解產品風險,如有需要應諮詢專業建議。~

重要聲明:

以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account